{
    "nct_id": "NCT03813615",
    "official_title": "Preoperative Aerobic Training for Solid Tumors (PRESTO 1): A Phase 0/1a Digitized Clinical Trial",
    "inclusion_criteria": "Phase 0 (Proof-of-Concept)\n\n* Patients with one of the following:\n\n  * Early-stage breast cancer having completed participation in IRB# 15-147\n  * Diagnosed with the prespecified solid tumors: endometrial, breast or prostate cancer\n  * Underwent a diagnostic lung biopsy within 14 days prior to enrollment\n  * Age >18 years\n  * BMI ≤ 40\n  * Has ≥ 20 mg of fresh normal lung and suspicious lung tissue from the standard of care diagnostic biopsy available for snap freezing and single-cell sequencing (lung patients only)\n  * At least a 2-week window from study enrollment to scheduled surgical resection (patients with prespecified solid tumors only)\n  * Performing less than 30 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluation by self report If > 30 minutes but less than 90 minutes, patients may be eligible, at the discretion of the PI.\n  * Cleared for exercise participation as per screening clearance via PAR-Q+\n  * Willingness to comply with all study-related procedures\n\nPhase 1a (Dose-Finding/Escalation)\n\n* Patients with operable untreated prostate cancer scheduled for surgery\n* At least a 2-week window from study enrollment to scheduled surgical resection (patients with prespecified solid tumors only)\n* Age > 18 years\n* BMI </=40\n* If BMI >40, patients may be eligible, at the discretion of the PI\n* Performing </= 30 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluation by self report If > 30 minutes but less than 90 minutes, patients may be eligible, at the discretion of the PI.\n* Cleared for exercise participation as per screening clearance via PAR-Q+\n* Willingness to comply with all study-related procedures\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Use of any selective estrogen receptor modulator or aromatase inhibitor within 6 months of study entry, including, but not limited to: tamoxifen, raloxifene, arzoxifene, acolbifene, anastrozole, exemestane, and letrozole (for preoperative breast, endometrial, and prostate patients in Phase 0 only)\n* Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound the effect of exercise on study outcomes\n* Men receiving GNRH agonists and antagonists as well as any antiandrogrens\n* Any neoadjuvant anticancer treatment of any kind for the cancer of interest\n* Any history of systemic anticancer therapy\n* Any other diagnosis of invasive cancer currently requiring active treatment\n* Metastatic malignancy of any kind\n* Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation.",
    "miscellaneous_criteria": ""
}